A pipeline to create predictive functional networks: application to the tumor progression of hepatocellular carcinoma by Folschette, Maxime et al.
HAL Id: hal-02095930
https://hal.archives-ouvertes.fr/hal-02095930v4
Submitted on 13 Dec 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
A pipeline to create predictive functional networks:
application to the tumor progression of hepatocellular
carcinoma
Maxime Folschette, Vincent Legagneux, Arnaud Poret, Lokmane Chebouba,
Carito Guziolowski, Nathalie Théret
To cite this version:
Maxime Folschette, Vincent Legagneux, Arnaud Poret, Lokmane Chebouba, Carito Guziolowski, et
al.. A pipeline to create predictive functional networks: application to the tumor progression of hep-




A pipeline to create predictive functional
networks: application to the tumor progression of
hepatocellular carcinoma
Maxime Folschette1,2,3,4,5, Vincent Legagneux2, Arnaud Poret4, Lokmane Chebouba4,6,7, Carito
Guziolowski4,6* and Nathalie Théret1,2*
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Background: Integrating genome-wide gene expression patient profiles with
regulatory knowledge is a challenging task because of the inherent heterogeneity,
noise and incompleteness of biological data. From the computational side, several
solvers for logic programs are able to perform extremely well in decision problems
for combinatorial search domains. The challenge then is how to process the
biological knowledge in order to feed these solvers to gain insights in a biological
study. It requires formalizing the biological knowledge to give a precise
interpretation of this information; currently, very few pathway databases offer this
possibility.
Results: The presented work proposes an automatic pipeline to extract
automatically regulatory knowledge from pathway databases and generate novel
computational predictions related to the state of expression or activity of
biological molecules. We applied it in the context of hepatocellular carcinoma
(HCC) progression, and evaluate the precision and the stability of these
computational predictions. Our working base is a graph of 3,383 nodes and
13,771 edges extracted from the KEGG database, in which we integrate 209
differentially expressed genes between low and high aggressive HCC across 294
patients. Our computational model predicts the shifts of expression of 146 initially
non-observed biological components. Our predictions were validated at 88% using
a larger experimental dataset and cross-validation techniques. In particular, we
focus on the protein complexes predictions and show for the first time that
NFKB1/BCL-3 complexes are activated in aggressive HCC. In spite of the large
dimension of the reconstructed models, our analyses over the computational
predictions discover a well constrained region where KEGG regulatory knowledge
constrains gene expression of several biomolecules. These regions can offer
interesting windows to perturb experimentally such complex systems.
Conclusion: This new pipeline allows biologists to develop their own predictive
models based on a list of genes. It facilitates the identification of new regulatory
biomolecules using knowledge graphs and predictive computational methods. Our
workflow is implemented in an automatic python pipeline which is publicly
available at https://github.com/LokmaneChebouba/key-pipe and contains
as testing data all the data used in this paper.
Keywords: Data and network integration; Discrete modeling; Hepatocellular
carcinoma; Signaling and regulatory knowledge; KEGG
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1 Background
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer,
which counts for more than 800,000 deaths each year. The incidence of HCC is as-
sociated with the development of chronic hepatitis mainly linked to viral infection,
alcohol consumption and non-alcoholic fatty liver disease (NAFLD) [1]. Lifestyles
[2] and environmental pollution such as particulate matter air pollution [3] also
contribute to increase burden in HCC worldwide. HCC is a heterogeneous disease
and various genomic alterations associated with the etiologies and the stages of
the pathology have been widely documented [4, 5]. A pivotal step in the course
of HCC progression is the epithelial-mesenchymal transition (EMT) which allows
hepatocytes to transdifferenciate into mesenchymal phenotype whereby escaping to
host control and acquiring anti-apoptotic and motility features [6]. Upregulation
of EMT markers has been associated with tumor aggressiveness and bad prog-
nosis [7, 8] and associated with inflammatory microenvironment [9]. However, in
vivo monitoring of EMT processes remains difficult, due to the spatio-temporal dy-
namics of these molecular events and the snap-shot nature of biopsies sampling.
Understanding EMT to identify new therapeutic targets require integrative and
modeling approaches.
To build computational models and integrate experimental data on molecular
events, pathway databases can be used. However, despite the fact that numerous
publicly available pathway databases currently exist, compiling hundreds of signal-
ing pathways for various biomolecules, very few formal representations linked with
automatic inference processes have been proposed so far [10]. The main difficulty
appears to be the transfer from the biological representation of a pathway towards
a logic knowledge base. Currently, pathway repositories, such as Reactome [11],
Pathway Commons [12], KEGG [13], or OmniPath [14] propose their own tools to
build graphs. Some of these tools are the Cytoscape [15] plugin CyPath2, PCViz
for Pathways Commons; pypath for OmniPath; and ReactomeFIViz [16] for Reac-
tome. However, the resultant graphs are difficult to be transferred into mechanistic
models because the notion of causality is often misinterpreted. This misinterpreta-
tion is due to the lack of a formal causal representation of biochemical reactions
such as protein complexes assemblies. For instance tools such as CyPath2, PCViz,
ReactomeFIViz, and pypath model protein complexes using a relation of causality
between the protein complex members (protein complex members are the cause and
consequence of each other); while in our modeling choice, protein complexes may
be triggering other reactions, and their presence is a consequence of the presence of
their members. Knowing that signaling cascades are represented by multiple com-
plexes assemblies, this misinterpretation impacts importantly the construction of a
mechanistic model when using pathway databases. On the other hand, such tools
are very useful to compute topological scores, perform statistical analyses, and to
integrate gene expression measurements using enrichment analyses [17]. They re-
main, however, limited to extract logical consequences of the representation of the
biological mechanisms.
The sign-consistency framework proposes a way to automatically confront the
logic of large-scale interaction networks and genome-wide experimental measure-
ments, provided that a signed oriented network is given and that the experimental
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measurements are discretized in 3 expression levels (up-regulated, down-regulated
and no-change). This framework, introduced in [18], has being applied to model
middle- and large-scale regulatory and signaling networks. The two most recent im-
plementations of it are by the means of integer linear programming [19] and logic
programming. The latter, implemented in a tool named Iggy [20], presents some key
aspects: (i) it provides a global analysis applying a local rule which relates a node
with its direct predecessors, (ii) it handles a network composed of thousands of com-
ponents, (iii) it allows the integration of hundreds of measurements, (iv) it performs
minimal corrections to restore the logic consistency, and (v) once the consistency
is restored, it allows to infer the behaviour (up, down, no-change) of components
in the network that were not experimentally measured. In this work we apply this
sign-consistency framework to model HCC progression.
Our case study is composed of two input data which were publicly available. First,
gene expression data from patients with HCC was extracted from the International
Cancer Genome Consortium (ICGC) database [21]. Based on the EMT signature
from MSigDB [22], HCC samples were clustered into either agressive HCCs (high
EMT gene expression) or non-agressive HCCs (low EMT gene expression). Sec-
ond, the up-stream events of the regulatory events of these genes were obtained by
querying automatically KEGG to build a causal model from this database. We used
Iggy to study what are the regulatory events that explain the differential expres-
sion between low and high aggressiveness from the KEGG interaction knowledge
(network of 3,383 nodes and 13,771 edges). We discovered that 146 nodes were
predicted, of them 33 refer to gene expression, 110 were protein activities, and 3
were protein complexes activities. 88% of the predictions were in agreement with
the ICGC gene expression measurements. Importantly, we predicted the activation
of NFKB1/BCL3 and NFKB2/RELB complexes, two critical regulators of NFKB
signalling pathway implicated in tumorigenesis. Finally, we proposed a method to
discover sensitive network regions that explains HCC progression. This means net-
work components which were highly constrained by multiple experimental data
points that could be interesting to target in order to obtain significant changes in
the system behavior. We provide a list of 27 nodes discovered by this approach,
including TP53.
These results were obtained with a new pipeline developed for this work and
freely available online. This pipeline, based on an initial network and a list of genes
of interest, allows to extract a functional network based on this list, apply the
prediction method described above, and run stability analyses on the result.
2 Results
2.1 Overview of the pipeline
We introduce key-pipeline: a Python package implementing the workflow for identi-
fying key protein complexes associated to tumor progression. The general pipeline
implemented is depicted in Figure 1. It receives as input data: a list of differentially
expressed genes, a graph describing signed and directed signaling interactions, and
a set of excluded genes to be filtered out from the graph. Our software allows re-
searchers to: 1) construct the set of observations, and the set of gene names from a
file of differentially expressed genes (in CSV format with 3 columns: genes names,
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log2(fold-change) and adjusted p-value), see Section 5.1; 2) extract a specific reg-
ulatory and signaling network associated with the input genes list from a signed
interaction graph (based on KEGG regulatory knowledge, see Section 5.2); 3) ap-
ply the Iggy tool to compute the predictions based on the sign-consistency modeling
(see Section 5.3); 4) perform robustness and stability analyses (see Section 5.4); and
finally 5) generate plots of these analyses. The pipeline provides a command line in-
terface (CLI), it can be customized by entering file names as arguments. By default,
all the steps of the methods will be executed, but the user can run specific steps
by using the argument --steps. This general pipeline implements all the steps in
the workflow described from Section 5.2.2 to Section 5.4.2 and depicted in Figure 1.
Each step will output one or more files. In general, the output of one step corre-
sponds to the input of another one. This enables a straightforward application of
the workflow for users without programming expertise. We refer the reader to the
online documentation for an in-depth description of installation and usage[1].
2.2 Integration of Gene Expression in Signaling and Regulatory Network
A first interaction graph was built from the KEGG Pathway database (see Sec-
tion 5.2). This graph was composed of 41,546 interactions (gene transcriptions,
protein signaling, protein formation and complex formations) and 8,861 compo-
nents (genes, proteins and protein complexes). It is available as input-data with the
pipeline[2]. Using our pipeline (Figure 1, step 2: Pathrider), the 1913 differentially
expressed genes between low and high aggressive tumors were used as input to ex-
tract a subgraph from the KEGG pathways graph. Only 209 genes from the 1913
were identified and used to extract upstream regulatory events (Additional file 1:
Table S1). In this step the biomolecules associated to the 4,220 genes whose expres-
sion is undetectable were filtered out. The resultant graph was composed of 13,771
interactions and 3,383 components (Additional file 1: Figure S1). The content of
the graph is available in Additional file 2: File graph.sif in SIF format and in
Additional file 2: File graph.cys as a Cytoscape session.
The final graph contains mostly activations (11,661 versus 2,110 inhibitions); this
follows the same activation/inhibition distribution than for the KEGG graph. Only
209 nodes have observations attached to them, provided by the differential anal-
ysis of Section 5.1, leaving most nodes unobserved and subject to computational
predictions. Finally, the presence of nodes gathering a lot of incoming or outgoing
interactions is noteworthy:
• The largest in-degree is 92 (concerning nodes PIK3R6 prot, PIK3CG prot and
PIK3R5 prot);
• The largest out-degree is 79 (concerning nodes PRKACB prot, PRKACA prot);
• Two nodes (MAPK3 prot and MAPK1 prot) both have the maximal total degree
of 107, with 56 incoming and 51 outgoing interactions.
Such “hub” nodes, having an influence to and from a lot of other components, have
a high impact on the rest of the network and produce less consensual labelings.
[1]File README.md at https://github.com/LokmaneChebouba/key-pipe/
[2]Input data are available at https://github.com/LokmaneChebouba/key-pipe/tree/master/example
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2.3 Computational Predictions Validation
We applied the sign-consistency modeling on the final KEGG signed graph obtained
in the previous section and the 209 observations derived from the differential analy-
sis (see Section 5.1). Iggy (Figure 1, step 3) returns 146 predictions, that is, couples
of (x, s), where x is a node of the graph (either a gene, a protein or a protein com-
plex) and s is its consensual sign across all consistent labelings, as given by the
pred(x) function (see Section 5.3). s ∈ {−, 0,+} refers to a down-regulation (or in-
activation), unchanged behavior, and up-regulation (or activation) of the behavior
of biomolecule x under the low versus high aggressive tumor comparison. In the
case where x is a protein complex or a protein, the predicted sign will denote a pos-
itive, negative or neutral shift in the effect of the protein or complex towards their
targets. In Table 1 we show the 146 obtained predictions after minimal correction,
in summary we obtained:
• 92 over-expressions (+): 77 proteins, 13 genes, and 2 protein complexes,
• 54 under-expressions (−): 33 proteins, 20 genes and 1 protein complex.
The list of all predictions is plotted on the KEGG graph in Additional file 1:
Figure S2 and on the volcano plot of differential gene expression in Additional file
1: Figure S3. The minimal correction set (MCoS) detected to recover the consistency
between the graph causality and the data, was composed of a single repair: adding
an influence towards node PMAIP1 gen resolves the conflict. This repair is shown
in Additional file 1: Figure S4. In the end, 3,026 nodes remain not observed nor
predicted. Iggy takes one minute to compute these results on a standard laptop
computer[3].
Among the 146 predictions, 143 have a name that matches with a gene name
identified in HCC from the ICGC database, but that were not selected in the 1913
genes differentially expressed (< −0.5 for down-regulated and > 2 for up-regulated
in aggressive HCC). If we remove all thresholds and thus consider any positive fold-
change as an over-expression, and any negative fold-change as an under-expression,
then 82 components predicted + are coherent with the ICGC data and 8 are not; 44
components predicted − are coherent with the ICGC data and 9 are not. This ratio
of 88% of matching predictions speaks in favor of our choice of applying Iggy to
this specific biological system, with respect to the currently available data in KEGG
and ICGC databases. This comparison can be visualized on the volcano plot of gene
differential expression in Additional file 1: Figure S3, and is also depicted on the
KEGG graph in Additional file 1: Figure S5. The list of predictions not matching
with experimental expression data is given in Additional file 1: Table S2.
2.4 Impact of data incompleteness on computational predictions
This section presents the results of the two validation analyses applied on the sam-
pling of observations described in Section 5.4. The objective is to observe the impact
of data incompleteness in our computational predictions. For this, we observed and
tracked across the samples the level of precision and the quality of the information
contained in the predictions (See Figure 1, step 4).
[3]Laptop computer containing an Intel Core i7-5600U CPU with 4 threads of
2.60GHz and running Fedora 27 64 bits.
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2.4.1 Precision Rate
The first approach (see Section 5.4.1) aims at observing the evolution of the pre-
dictions precision when using an increasing amount of data-points of the original
dataset (see Figure 2). We can observe a clear convergence of the precision score to-
wards 0.88 corresponding to the precision found with the full dataset, which shows
that our complete predictions do not lie in a local extremum.
2.4.2 Stability Study
The second approach (see Section 5.4.2) consists in observing “good”, “bad” and
“missing” predictions for each of the experiments (samplings < 100%) compared
to the 100% sampling. Figure 3 computes the minimum, maximum, median and
mean of each such category. Globally, we can observe that the mean and median
number of “bad” predictions, that is, predictions that are different with a subset
of observations than with the complete set of observations, are really low, below
4% for all samplings. Nevertheless, some samplings show a high proportion of such
“bad” predictions. Moreover, the number of “missing” predictions is very high for
low samplings, which assesses that there is too little information to obtain complete
results. Overall, “bad” predictions tend to decrease after the 65% sampling, along
with “missing” predictions that decrease all the way, making “good” predictions
mathematically increase.
2.4.3 Insights of the Stability Results
The analyses of the experiments shown in the previous subsections show that the
“badly” predicted components for subsets of observations are always the same 28
nodes, listed in Additional file 1: Table S3. These nodes belong to the same region
of the graph, which is depicted in Additional file 1: Figure S4. Actually, a group
of 27 of these nodes are strongly linked and always change their coloring together.
When searching inside the graph topology, one can remark that this group is tightly
linked to the node TP53 prot, which is also part of the group. This protein acts as
a “hub” inside the graph, having a high degree (25 ingoing and 28 outgoing edges).
It therefore controls closely, if not directly, a lot of other components that change
their sign as soon as it does so, rendering the whole group of predictions unstable.
The reason of this instability is that TP53 prot directly influences node PMAIP1 gen
which is involved in the only MCoS repair in our graph: the node PMAIP1 gen is
indeed observed as over-expressed (+) but 3 other under-expressed (−) observa-
tions contradict this one: CCNG1 gen, SHISA5 gen and TP73 gen. This leads to an
inconsistency, as explained in Section 2.3. The repair here consists in adding an
edge towards PMAIP1 gen that models missing information, in order to remove this
inconsistency, as shown in Additional file 1: Figure S4. In practise, this renders
PMAIP1 gen “silent” regarding TP53 prot, which then takes the coloring of the
other observations (under-expression). Nevertheless, when picking random sets of
observations, we sometimes fall in cases where among these 4 observations, only
PMAIP1 gen is selected; in this case, no repair is needed and TP53 prot is predicted
as over-expressed, also leading to 26 different predictions in downstream nodes.
Finally, the last unstable node is PMAIP1 prot: in the case where PMAIP1 gen is
part of the randomly picked observations, it is straightforwardly predicted over-
expressed while in the converse case, where PMAIP1 gen is not part of the observa-
tions, it is indirectly influenced by TP53 prot and thus predicted under-expressed.
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Such unstable predictions can be regarded as not very robust because they are
changeable depending on the number of observations taken into account. On the
other hand, all other predicted components are stable and can be considered as
robust since, when they are predicted, their prediction matches the one obtained
using all the observations. The list of stable and unstable predictions is given in
Additional file 1: Table S3.
2.5 Biological Validation of the Computational Results
Among the computational predictions given in Section 2.3, some of them are of
particular interest in regard to the expression data from ICGC. In this section, we
detail and validate them biologically.
2.5.1 Activation of NFκB signaling in aggressive HCC
Based on the regulatory model (Additional file 1: Figure S1) and differential expres-
sion of mRNA between low and high aggressive HCC (see Section 5.1), the algorithm
Iggy predicts the activation of complexes NFKB1::BCL3 and NFKB2::RELB and
the deactivation of complex JUND::NACA. By activation of the complexes we mean
that in order to explain the high-aggressive versus low-aggressive tumor gene ex-
pression datasets, these complexes have to increase their activity. For example, if
NFKB1::BCL3 is activated, then we deduce that its effect on gene IL10 (regulated
positively by this complex, Additional file 1: Figure S6) is positive, meaning that
the level of gene IL10 may increase if it was only regulated by NFKB1::BCL3. pro-
tein complex prediction is a novel information since it was not present in the initial
experimental data of gene expression.
Among them, two complexes are related to NFκB signaling and are predicted
as activated: NFKB1::BCL3 and NFKB2::RELB. NFKB1, NFKB2 and RELB are
three subunits of the transcription factor complex nuclear factor-kappa-B (NFκB)
which consist in a homo- or heterodimeric complex formed by Rel-like domain-
containing proteins p65 (RelA), RelB, c-Rel, p50 (NFKB1), and p52 (NFKB2).
The NFκB signaling system acts through canonical and non canonical pathways
which are induced by different extracellular signals [23]. The canonical pathway can
be induced by TNF-α, IL-1 or LPS stimulation and requires NF-kappa-B essential
modulator (NEMO) while the non-canonical pathway is induced by other ligands
such as CD40 ligand (CD40L), receptor activator of nuclear factor kappa-B ligand
(RANKL), B-cell activating factor (BAFF) and lymphotoxin beta (LTb). Upon lig-
and binding to its receptor, the signaling cascades control the degradation of IkB
proteins (inhibitor of NFκB) and precursor processing including NFKB1 (p105) and
NFKB2 (p100) which are proteolytically activated to p50 and p52 respectively. B-
cell chronic lymphatic leukemia protein 3 (Bcl3) is a member of IkB family that are
inhibitors of NFκB members. BCL3 associates with NF-kappa B in the cytoplasm
and prevents nuclear translocation of the NFKB1 (p50) subunit. When phospho-
rylated, BLC3 is activated and associates with NFKB1 in the nucleus to regulate
NFκB target genes [24]. NFκB system is involved in the regulation of numerous bi-
ological processes including inflammation, cell survival and development. Regarded
as protective against aggression from environment in normal physiology, alteration
of NFκB signaling pathways has been associated with various diseases such as in-
flammatory disease and cancer [25, 26]. In HCC, NFκB pathway was shown to be
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deregulated in tumor and underlying fibrotic livers [27, 28]. Notably, increased ex-
pression of p50 and BCL3 has been reported in tumors compared with adjacent
tissues [29] and p50 expression was associated with early recurrence of HCC [28].
In order to evaluate our predictions about the activation of NFKB1::BCL3 and
NFKB2::RELB complexes, we thought to search for expression of genes regulated by
these complexes. For that purpose, we take advantage of the NFκB-dependent signa-
ture available in MSigDB [22, 30]. We selected the HALLMARK TNFA SIGNALING VIA NFKB[4]
signature which contains 200 genes regulated by NFκB in response to TNF. As
shown in Additional file 1: Figure S7A, we demonstrated that these genes were
more expressed in high aggressive HCC when compared with low aggressive ones
supporting the activation of NFκB signaling. More specifically, we searched for
expression of genes targeted by NFκB-non-canonical pathway, including the cy-
tokines CCL19 and CCL21. These genes are regulated through the activation of
NFKB2::RELB complexes and their expression was increase in high aggressive
HCC thereby confirming the prediction (Additional file 1: Figure S7B).
Another prediction was the down-regulation of JUND::NACA complex that was
previously demonstrated to regulate osteocalcin [31]. This prediction is mainly con-
ditioned by osteocalcin (BGLAP) expression data that was found down-regulated
in the aggressive HCC (−1.3 fold-change between aggressive versus non-aggressive
HCC). Such observations are in accordance with previous reports showing that os-
teocalcin was down-regulated in the serum of HCC patients when compared with
healthy controls [32]. As shown in Additional file 1: Figure S8A, we showed that
both JUND and NACA gene expressions were down-regulated in aggressive HCC
supporting the prediction of down-regulation of the complexes JUND::NACA. Im-
portantly, the targets of JUND::NACA complex including LRP5 and LRP6 genes
were predicted as down-regulated by our model (Additional file 1: Figure S6). The
down-regulation of LRP5 in aggressive HCC was validated in HCC data but was
not significant for LRP6 probably due to the low level of gene expression (Addi-
tional file 1: Figure S8B). According with this, the up-regulation of LRP6 through
JUND::NACA complexes was clearly demonstrated in osteoblasts [33].
To conclude, model predictions were validated by data analyses and are in ac-
cordance with the literature. Importantly, this is the first report describing the
activation of NFKB2::RELB complex and the down-regulation of JUND::PACA
complex in aggressive HCC.
3 Discussion
The understanding of tumor progression dynamics is extremely difficult when con-
sidering the snap-shot nature of data from patients. However, compiling information
from a wide spectrum of tissue samples can be used for modeling evolutive stories.
The complexity of molecular events implicated in hepatocellular carcinoma progres-
sion is directly associated with its various etiologies that differently contribute to
tumor initiation, growth and evasion. During last decades, multiscale omics data
analysis of genome and proteome allowed to explore molecular networks associated
with HCC and mathematical models have been developed namely to predict cancer
[4]Id: M5890, available at http://software.broadinstitute.org/gsea/msigdb/geneset_page.jsp?
geneSetName=HALLMARK_TNFA_SIGNALING_VIA_NFKB
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cell behavior [34]. Accordingly, an elegant discrete model was developed by [35] to
explore TGF-β signaling pathway during epithelio-mesenchymal transition in HCC.
However, HCC results from complex interactions between the tumor cells and the
microenvironment involving stromal cells and extracellular matrix. Molecular bio-
logical data from tumor tissues recapitulate all this information and we need to build
an unique large-scale model without a priori to take into account such complex-
ity. For that purpose, we propose here an original approach aiming at integrating
experimental data on a regulatory graph extracted from the KEGG database to
predict new markers and regulators of HCC progression.
Based on EMT gene expression signature from MSigDB [22] we first separated
low from high aggressive HCC samples stored in the ICGC database [21] and next
we sought to predict the regulatory pathways implicated in this transition. For that
purpose, we built a model by querying the KEGG database using the KEGG API
to extract an initial network. We have implemented a tool, Pathrider, to allow us
extracting a directed and signed sub-network, from the previously obtained network,
by using the up-stream events of a list of target genes. Importantly, our modeling
choices allowed us to connect protein complexes to their members, and to label
network nodes of type gene and protein. This separation of concepts is particularly
valuable when modeling gene expression.
The publicly available knowledge base KEGG, gathering curated signaling and
regulatory processes, is well structured to automatically extract mechanistic models
from it. In particular: (i) the information concerning gene transcription and signal-
ing modifications is differentiated, (ii) the network nodes identifiers are unique, and
(iii) the biological processes, such as phophorylation or gene-regulation, are clearly
represented.
Using Iggy, it was possible to confront the logic of a large-scale KEGG network
(3,383 nodes, 13,771 edges) to the expression of genes differentially expressed be-
tween high-aggressive and low-aggressive HCC. In this context, we were able to
propose an integrated model of HCC progression and to predict the regulation of
new biomolecules including genes, proteins and complexes. A major finding is that
the model predicted the behavior of 146 network components that were associ-
ated with the progression of tumors. 88% of the computation model predictions
were validated with the ICGC data-set and by using cross-validation techniques,
thereby demonstrating the quality of the model. Conversely, 12% of the predictions
did not match the experimental data, however 10 of these components are part of
gene/protein couples leading to linked predictions. In addition, all of these compo-
nents but one had a low expression change (less than 1 in absolute value) along
with a high p-value (above 10−2) that might explain the inconsistency. The remain-
ing one is THBS1 gen (thrombospondin 1 gene) with a fold-change of 1.996, and is
also part of the cluster of unstable predictions depicted in Section 2.4.3. Indeed,
we discovered a subset of 28 network nodes that were very sensitive to the exper-
imental data. That is, they were strongly constrained by a subset of experimental
observations. We notice that these nodes behave as hubs in the network, and can
be candidate to experimental stimulation or inhibition in order to affect the system
behavior.
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The most interesting prediction was the activation of protein complexes related to
NFκB signaling since complexes formation is directly responsible for signal trans-
duction [36]. While the role of NFκB signaling pathway has been widely docu-
mented in chronic liver disease [37], the activation of NFKB1/BCL-3 complexes in
aggressive HCC has never been reported. The IκB protein BCL-3 acts both as a
co-activator that form complexes with NFKB1(p50) dimers to promote genes [38]
and as a co-repressor of gene transcription by stabilizing P50 homodimers on DNA
promoters [39]. Predicted activation of such complexes in aggressive HCC revealed
the ambivalent role of NFKB-mediated inflammatory response during the course of
tumor progression [40].
4 Conclusion
The present study is general to be applied to other biological data from cancers
or other disease. In the future, we would like to use logic programming to target
the combinatorics of sensitive regions in a regulatory graph with respect to gene
expression profiles, in order to propose regulatory elements for clinical therapy.
Another perspective is to apply our method to subsets of patients, and observe if
there are clusters of patients that have specific computational model signatures for
HCC progression.
5 Methods
5.1 Identification of gene differentially expressed between low and high aggressive
HCC
Normalized HTseq counts and clinical data were retrieved from the LIHC-US
project[5] (NCI, TCGA-LIHC). These files were downloaded on 2016-07-19, cor-
responding to release 21. At this date, LIHC-US dataset comprised 294 donors and
345 samples; among them, we selected samples corresponding to solid primary tu-
mors, based on clinical data, by selecting entries containing the expression ”Primary
tumour - solid tissue” in the specimen table (7th field). This allowed selecting
one sample for each of the 294 donors. Data retrieval and filtering workflow is de-
tailed in Additional file 3: File dataset filtering.sh.
From this filtered dataset, we extracted a two-dimensional table of expression val-
ues (converted in log2) for 20,502 genes in 294 LIHC samples. Based on the bimodal
distribution of these expression values, we discarded genes whose expression is unde-
tectable (4,220 genes), keeping 16,282 genes. Expression values were normalized by
the median value in each sample. Based on the established link between epithelial-
mesenchymal transition (EMT) and tumor aggressiveness [41], we used the MSigDB
[42] set of 200 genes termed HALLMARK EPITHELIAL MESENCHYMAL TRANSITION[6]
from the Broad Institute as a molecular signature of aggressiveness. From the LIHC
dataset, we extracted a table of expression values for 195 entries of this EMT signa-
ture for each of the samples (5 genes were undetectable). Based on the expression
values of the EMT signature, LIHC samples were classified (hierarchical clustering of
[5]All ICGC data used in this work are publicly available at https://dcc.icgc.org/
releases/release_21/Projects/LIHC-US
[6]Id: M5930, available at http://software.broadinstitute.org/gsea/msigdb/geneset_page.jsp?
geneSetName=HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
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euclidean distances) into three groups termed low EMT (70 samples), medium EMT
(154 samples), and high EMT (70 samples). The result of this clustering analysis is
available in Additional file 1: Figure S9. Samples corresponding to the medium EMT
group were discarded and a differential expression analysis was performed by com-
puting a non-parametric Mann-Whitney test for all the 16,282 genes between the
low EMT and high EMT groups. p-values were adjusted for multiple analyses by
the Benjamini & Hochberg method. The volcano plot of Additional file 1: Figure S10
represents fold-changes (log2) against adjusted p-values (− log10) and the raw data
are available online as input data of the pipeline[7].
We focused on genes with an adjusted p-value below 10−5. Genes with a
log2(fold-change) greater than 2 were considered as over-expressed (821 genes),
whereas those with a log2(fold-change) lower than 0.5 were considered as under-
expressed (1,092 genes). Together, these 1913 differentially expressed genes, listed
in Additional file 2: File diffexp filtered.csv were subsequently used to extract
a regulatory network, as explained in Section 5.2, and then used as observations for
the coloring propagation process, as detailed in Section 5.3. The full list of differ-
entially expressed genes is available in Additional file 2: File diffexp full.csv.
The workflow of data clustering and differential analysis is available in Additional
file 3: File diffexp and clustering.R.
To further validate the clinical relevance of the groups of HCC samples identi-
fied by the hierarchical clustering method, we compared this classification obtained
with the EMT signature to a classification obtained with markers established as
predictive of recurrence, which is a major clinical outcome of tumor aggressiveness.
For that purpose, we used the Seoul National University recurrence (SNUR) signa-
ture [43] that previously permitted to classify HCC samples from TCGA database
[44] and we compared clusters identified by hierarchical clustering method with
SNUR groups. Note that LIHC primary tumors correspond to 294 samples but
only 183 are annotated with SNUR score. Clustering methods were applied to all
the 294 samples used in this study and comparisons of clustering classes were made
for the 183 samples. When hierarchical groups were compared to SNUR groups,
we found a χ2 test p-value of 3.81 × 10−14, with 9% of class 1 (low EMT) belong-
ing to the low-recurrence group, and 83% of class 3 (high EMT) belonging to the
high-recurrence group. Together, these data demonstrate the accuracy of clustering
method to identified low and high aggressive HCC samples.
5.2 Building a signed interaction graph from the KEGG Pathway database
For this case study, we used a human signaling network derived from the KEGG
Pathway database [13]. 154 human signaling pathways were fetched using the KEGG
API and converted to SIF (Simple Interaction Format) in order to provide KEGG’s
knowledge as a graph representation. This section summarizes how this network
was built. A more in-depth description is available in Additional file 1 as a Sup-
plementary Material & Methods. This step of automatic reconstruction of a causal
graph from KEGG constitutes one of the novel contributions of the methodological
results of this paper.
[7]Files GSEA EMThigh vs EMTlow diffexp.csv (differential expression) and
LIHC primary weakly expressed genes.txt (blacklist of weakly expressed genes) at
https://github.com/LokmaneChebouba/key-pipe/tree/master/example.
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5.2.1 Signed interaction graph built from KEGG’s regulatory knowledge
To model the KEGG regulatory knowledge we imposed a distinction between
nodes representing genes and nodes representing proteins. In the KEGG Pathway
database, this distinction is implicitly embedded in the relation types, particularly
PPrel edges (protein-protein relations) and GErel edges (gene expression relations).
PPrel edges indicate that both source and target nodes are proteins. GErel edges
indicate that source nodes are transcription factors and that target nodes are genes.
Therefore, to explicitly differentiate genes and proteins, the source nodes of GErel
edges were suffixed with prot and the target nodes were suffixed with gen. Con-
cerning PPrel edges, both the source and target nodes were suffixed with prot.
Differently to what proposed by KEGG maps, we modeled protein complexes ex-
plicitly by imposing two relations:
A prot PPrel A prot::B prot
B prot PPrel A prot::B prot
where A prot::B prot refers to the protein complex formed by proteins A and B.
Furthermore, in order to link genes and their products, a relation type (initially
absent in the KEGG KGML model) was added: the GPrel type (gene-protein rela-
tions). For each node C modeling a protein, a GPrel edge starting from its corre-
sponding gene and ending on C was added:
C gen GPrel C prot
These added nodes therefore model the corresponding gene products and the GPrel
edges model the protein formation given a gene expression, as illustrated in Addi-
tional file 1: Figure S11 and Figure S12. Note that without GPrel nodes, the graph
is much more disconnected and the predictions are fewer and of worse quality, as
showed in Additional file 1: Table S4 and Table S5.
In addition to their relation types, the edges are annotated in KEGG with key-
words bringing details about the modeled interactions. Therefore, edge signs (role
of activator or inhibitor) were inferred using these keywords.
Altogether, the human signaling network extracted from KEGG was represented
as a signed interaction graph composed of protein signaling interactions, complex
formations, gene expression regulations and gene-protein relations; accordingly, the
nodes of this graph refer to genes, proteins and protein complexes. This decomposed
representation allowed us to map on this network data which corresponded only
to gene expressions, without assuming that gene expression correlates to protein
activity. This KEGG signed and directed graph is available as input data of the
pipeline implemented in this work[8].
5.2.2 Extracting up-stream signaling pathways
For this work, we implemented Pathrider [9] in order to extract a subgraph from the
KEGG generic human signaling network (obtained in the previous section). Given
a list of genes and a network, Pathrider will keep only the signaling pathways of the
network regulating the list of genes, that is, the upstream paths of the nodes in the
network that represent these genes. Pathrider will also filter out the biomolecules
[8]File hsa-2345-symb-nomulti-split-func-sign.sif at https://github.com/LokmaneChebouba/key-pipe/
tree/master/example.
[9]Available at: https://github.com/arnaudporet/pathrider
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in the graph (genes, proteins or protein complexes) that appear in a list of excluded
genes, which in practice refer to genes whose expression is undetectable. This tool
is included in the automatic pipeline we propose in this work (see Section 2.1).
5.3 Sign consistency - Iggy
Let G(V,E, σ) be an interaction graph, where V represents the set of nodes, E
the set of edges, and σ : E → {+,−} a labeling (activation or inhibition) of the
edges; and given experimental observations (e.g. gene expression profile) (S, µ),
defined by the set of experimentally measured biomolecules S ⊂ V and the mapping
µ : V → {−, 0,+}. The sign-consistency principle, implemented in Iggy [20], defines
the rules to integrate interaction and experimental knowledge. In order to do this, we
look for total labelings µt : V → {−, 0,+} that satisfy the following sign-consistency
constraints (see Figure 4):
• The observations must keep their initial labelings.
• Each labeling + or − must be justified by at least one predecessor.
• Each labeling 0 must have only predecessors labeled as 0 or a couple of + and
− labeled predecessors.
Given a particular biological instance for G and (S, µ), it usually happens that
many total labelings µt, satisfying the constraints, are proposed. For a set V of nodes
in our network and a set M of total labelings consistent with our observations, we
define the prediction function pred : V → {+,−, 0,∅} as follows:
pred(x) =

+ if ∀µ ∈M : µ(x) = +
− if ∀µ ∈M : µ(x) = −
0 if ∀µ ∈M : µ(x) = 0
∅ otherwise.
This prediction function is an output of the sign-consistency modeling approach,
and it can be seen as an inference mechanism that generates a sign for a node x only
if in all the consistent total labelings it was assigned the same sign among {−, 0,+}.
There may be nodes in V with non prediction value (∅) thus meaning that no
certain conclusion was possible to be inferred for them. Biologically, this prediction
function will allow us to label non experimentally observed nodes, meaning that
their shift of expression or activity can be inferred thanks to their connectivity to
other observed biomolecules in the graph.
Another possible output of the sign-consistency approach is a list of conflicts, in
the case where (S, µ) is not compatible with G. It particularly signals a conflict
between the sign of some biomolecules and the interaction network. One way to
fix such conflicts is to add artificial interactions in the network. Iggy allows to
automatically add a minimal number of such repairs, called minimal correction
set (MCoS). If several possibilities of repairs are possible, Iggy will compute them
all and the final set of predictions will correspond to the union of the predictions
obtained after each possible repair.
Given the combinatorial nature of this analysis, Iggy is implemented in Answer
Set Programming, in particular using grounder Gringo 3.0.5 and solver Clasp 3.1.3.
For this work, the reasoning of Iggy, parametrized with the mentioned constraints
and the MCoS repairs, is added to the automatic pipeline we provide.
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5.3.1 Modeling our case-study using sign-consistency: inputs and outputs of Iggy
Inputs. The signed interaction graph G(V,E, σ) was obtained from the KEGG
Pathways database as explained in Section 5.2. The gene expression profile (see
Section 5.1) is composed of experimental knowledge of 821 over- (sign ’+’) and
1092 under-expressed (sign ’−’) genes in in high aggressive tumors compared to
low aggressive tumors. From these differentially expressed genes, only 209 were
found in the KEGG graph matching nodes with a suffix ’ gene’. Thus, the set
of observations (S, µ) used for the sign-consistency analysis was composed of 209
elements.
Outputs. Following the sign consistency analysis, Iggy proposed predictions under
minimal MCoS repairs. The complete results are discussed in Section 2. It is impor-
tant to recall that since the graph G, obtained from KEGG, is composed of nodes
which represent genes, proteins, and protein complexes. The prediction function
pred(x) computed by Iggy for x ∈ V will assign signs mainly to protein and protein
complex nodes. In this way Iggy will allow us to infer the activity or expression
shifts of unmeasured biomolecules of the system.
5.4 Computational Validation of the results
Recall that to create the over- and under-expressed genes between low and high
aggressive tumors (see Section 5.1) we used thresholds of +2 and −0.5 on the value
of log2(fold-change). In this section, we aim at checking if these thresholds are
justified. To do this, we computed “sub-predictions”, that is, predictions on the
same extracted graph of Section 5.2 but with subsets of observations. To generate
these subsets of observations, we considered a range of samplings, from 10% to
95% of the complete observation set, with a step of 5%. For each sampling of
x%, 100 experiments were conducted, where an experiment consisted in randomly
picking x% of the over-expressed observations (+) and x% of the under-expressed
observations (−), and computing the predictions on this subset of observations.
The results are 1,800 such subsets of observations, and as many computed sets
of predictions on the nodes of the graph, hereafter called sub-predictions. These
sub-predictions have been exploited in two ways:
1 by comparing said sub-predictions with the available gene expression data
from ICGC that were already used for the differential analysis (Section 5.4.1),
and
2 by comparing said sub-predictions with the final predictions obtained with
100% of observations to witness their variability (Section 5.4.2).
Both approaches are explained below; they are implemented and added to the au-
tomatic pipeline we propose in this work.
5.4.1 Recovery rate of the sub-predictions
We computed a normalized score by counting the number of predictions matching
the related experimental fold-change from the ICGC data. For each experiment
result, this score s is given by the formula: s = m/t where m is the number of
matching predictions, that is, positive predictions with positive fold-changes and
negative predictions with negative fold-changes, and t is the total number of pre-
dictions. This allows us to assess the ability of our model to recover from missing
information (here, observations).
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5.4.2 Stability of the sub-predictions
In order to look at the stability of the predictions made on subsets of observations,
we also compared them to the final predictions using 100% of the observations. For
each predicted node in the 100% sampling set, and for each of its corresponding
sub-prediction in a lower sampling set:
• If the node is predicted and the prediction matches the one at 100% sampling,
this is considered a “good” prediction.
• If the node is predicted but the prediction is not the same as for 100% sam-
pling, this is considered a “bad” prediction, thus representing mathematical
non-monotonicity and biological sensitive components or potential targets.
• If the node is not predicted, this is called a “missing” prediction.
Counting the elements and observing the evolution of these categories allows us to
witness if lower samplings converge to the final sampling or not, independently of
any exterior data such as expression data.
List of abbreviations
HCC, Hepatocellular carcinoma; ICGC, the International Cancer Genome Con-
sortium; NAFLD, non-alcoholic fatty liver disease; EMT, epithelial-mesenchymal
transition; CLI, command line interface; MCoS, minimal correction set.
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Figure 1 Schema describing the pipeline for building networks and predicting regulatory nodes
(1) Using a list of differentially expressed genes, construct the set of gene names and the
corresponding set of observations (a sign is attributed for each gene: + when fold change > 2 or
− when fold change < 0.5 and adjusted p-value < 10−5); (2) Extract the upstream/downstream
signaling pathways for the set of genes from the signed interaction graph using Pathrider, a tool
developed in our team to this purpose. Given a list of excluded genes (such as invariant genes),
Pathrider filters these genes to reduce the graph size; (3) Check the sign consistency of our
datasets to produce signed predictions for unmeasured biomolecules using iggy tool; (4) Validate
the predictions made by iggy by computing sub-predictions (prediction 1, 2...n) using a sub-set of
observations (by default, it starts sampling from 10% to 95% of observations with a step of 5%
and a number of execution equal to 100), then compare it firstly with the differentially expressed
genes, and in a second time with the predictions obtained with all the set of observations; and (5)
Plot the precision scores for each sub-sets of the observations, and the stability of the prediction
compared to the predictions of the entire set of observations.
Figure 2 Precision scores of predictions obtained on samplings of the observations Boxplots of
the precision scores (ordinate) of the predictions obtained with 100 randomly picked samplings
(abscissa) of observations. Each box plot at abscissa x represents the distribution of the precision
scores of the predictions obtained when using only x% of the observations. The point at 100%
represents the prediction score of the predictions when using the complete set of observations.
Figure 3 Stability of the predictions for subsets of observations This figure summarizes the
stability of the predictions for all samplings of the observations, compared to the final predictions
with all 100% of observations. “Good” predictions (matching the 100% predictions) are depicted
in green, “Bad” predictions (predicted differently than the 100% predictions) in red and “Missing”
predictions (not predicted) in blue. For each category, four curves are plotted representing, from
top to bottom, the maximum, median, mean and minimum number of predictions of this type.
Curves are normalized to the number of predictions obtained for each set of sampled data.
Folschette et al. Page 18 of 19
Figure 4 Consistency constraints. Given a signed graph, where green edges depict activations,
and red edges, inhibitions, two partial labelings for the nodes A and B are proposed in the first
and second rows. In both cases there are 32 different possible labelings for C and D taking 3 signs
{+,−, 0} corresponding to colors green, red and blue, respectively. We depicted here only one
consistent and one inconsistent scenario according to the sign-consistency constraints.
List of positive (up-regulated) predictions
ADRA2A prot, BDKRB2 prot, BMP4 gen, CCL11 prot, CCL13 gen, CCL13 prot,
CCL17 gen, CCL17 prot, CCL19 prot, CCL21 prot, CCL22 prot, CCL26 prot,
COL1A1 prot, COL1A2 prot, COL3A1 prot, COL4A2 prot, COL4A3 prot, COL6A1 prot,
COL6A2 prot, COL6A3 prot, COMP prot, CTBP2 prot, CTSK prot, CXCL12 prot,
CXCL14 prot, CXCL5 prot, CXCL6 prot, DCN prot, DKK2 prot, DUSP4 prot, EFNB3 prot,
EIF4EBP2 prot, EPHA3 prot, FGF18 prot, FGF1 prot, FHL2 prot, FPR1 prot, GLI3 prot,
HGF prot, HHIP prot, HIF1A prot, HTR2B prot, ICAM1 gen, IL34 prot, IL6 prot,
JAG1 prot, KRAS gen, LAMA1 prot, LAMA2 prot, LAMC2 prot, LAMC3 prot, LIF prot,
NFATC1 prot, NFKB1::BCL3, NFKB2::RELB, NOTCH1 gen, NOTCH2 gen, NOTCH4 gen,
NR0B2 gen, NR0B2 prot, NR1H4 gen, NR1H4 prot, NR3C2 gen, NR3C2 prot, NRG3 prot,
NTF3 prot, NTRK3 prot, PMAIP1 prot, PPP2R2C prot, PRKG1 prot, PTGER1 prot,
PTGIR prot, PTH1R prot, PTHLH prot, PTPRR prot, RASAL1 prot, SCTR prot,
SEMA3C prot, SFRP1 prot, SFRP2 prot, SFRP4 prot, SFRP5 prot, SGK1 gen, SLIT2 prot,
TGFA prot, THBS2 prot, THRA prot, TNC prot, TNXB prot, VDR gen, VDR prot,
WTIP prot
List of negative (down-regulated) predictions
APAF1 gen, APAF1 prot, BAK1 gen, BAX gen, BID gen, CCL15 prot, CCL16 prot,
CHAD prot, CREB1 prot, CSNK2B prot, DKK4 prot, EIF2B4 prot, EIF2B5 prot,
ELMO1 prot, FOXO3 prot, IGFBP3 gen, IGFBP3 prot, JUND::NACA, LRP5 gen, LRP6 gen,
MDM2 gen, PHLPP1 prot, PIDD1 gen, PIDD1 prot, PPP2R5A prot, PPP2R5D prot,
PTEN gen, RAD9A prot, RFNG prot, RXRB prot, SENP2 prot, SESN1 gen, SESN1 prot,
SESN2 gen, SESN2 prot, SESN3 gen, SESN3 prot, SFN gen, SFN prot, SIVA1 gen,
SIVA1 prot, SLC38A9 prot, SPDYC prot, SREBF1 gen, SREBF1 prot, THBS1 gen,
THBS4 prot, THEM4 prot, THPO prot, TNFRSF10A gen, TNFRSF10B gen, TP53 prot,
TP73 prot, TSC2 gen
Table 1 List of all predictions returned by Iggy.
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Additional Files
Additional file 1 — Additional tables, figures and explanations
This PDF file contains additional figures and tables related to all parts of this manuscript, along with a detailed
explanation of the KEGG graph extraction that was summarized in Section 5.2.
Additional file 2 — Input data and results of the application of our pipeline regarding hepatocellular carcinoma
progression
This archive contains input and output data related to hepatocellular carcinoma agressiveness that were used in this
work to illustrate the benefits of our pipeline. The input data consists of differentially expressed genes (in CSV
format) and the KEGG graph extraction (in SIF format). The output data consists in a Cytoscape session to explore
the graph and the computational prediction results along with dynamic plots of the results (volcano plots, precision
and stability studies, in HTML format).
Additional file 3 — Additional information to generate differentially expressed genes from ICGC database
This archive contains a SH script to filter dataset and a R script for data clustering and differential analysis
